Yoon Hyuk, Park Young Soo, Lee Dong Ho, Seo Jae-Gu, Shin Cheol Min, Kim Nayoung
Departments of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do 463-707, Korea.
Departments of Internal Medicine, Seoul National University Bundang Hospital, Gyeonggi-do 463-707, Korea ; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 110-744, Korea.
J Clin Biochem Nutr. 2015 Sep;57(2):129-34. doi: 10.3164/jcbn.15-14. Epub 2015 Jun 30.
We assessed the effect of multi-species probiotic mixture on the changes in fecal microbiota and irritable bowel syndrome (IBS) symptoms. Eighty-one IBS patients were randomly assigned to receive either probiotic mixture (n = 39; containing Lactobacillus acidophilus, L. rhamnosus, Bifidobacterium breve, B. actis, B. longum, and Streptococcus thermophilus) or placebo (n = 42) for 4 weeks. A questionnaire regarding general symptom relief was administered. The change in total symptom scores (sum of 10 IBS symptoms) and subtotal scores in 4 domains (pain, constipation, diarrhea, and bloating/gas) were evaluated. The change in fecal flora was determined by quantitative real-time PCR. The concentration of probiotic strains significantly increased after ingestion in probiotics group (B. bifidum, p = 0.043; B. lactis, p<0.001; L. acidophilus, p = 0.016; L. rhamnosus, p<0.001). The proportion of patients with adequate symptom relief was higher in probiotics group than in placebo group (74.4% vs 61.9%, p = 0.230). The decrease in total symptom score over time was not significantly different between the groups (p = 0.703). Among subtotal scores of 4 IBS symptom domains, the time effect was significantly different for diarrhea-symptom score between the groups (p = 0.017). A 4-week administration of multi-species probiotic mixture significantly increased the fecal concentration of most probiotic strains and improved diarrhea-symptom scores in IBS patients.
我们评估了多菌种益生菌混合物对粪便微生物群变化及肠易激综合征(IBS)症状的影响。81例IBS患者被随机分为两组,分别接受益生菌混合物(n = 39;含嗜酸乳杆菌、鼠李糖乳杆菌、短双歧杆菌、嗜双歧双歧双歧杆菌、长双歧杆菌和嗜热链球菌)或安慰剂(n = 42)治疗4周。采用一份关于总体症状缓解情况的问卷进行调查。评估10项IBS症状总分及4个领域(疼痛、便秘、腹泻和腹胀/胀气)的分项得分变化。通过定量实时PCR测定粪便菌群的变化。益生菌组摄入后益生菌菌株浓度显著增加(两歧双歧杆菌,p = 0.043;乳酸双歧杆菌,p<0.001;嗜酸乳杆菌,p = 0.016;鼠李糖乳杆菌,p<0.001)。益生菌组症状充分缓解的患者比例高于安慰剂组(74.4%对61.9%,p = 0.230)。两组间症状总分随时间的下降无显著差异(p = 0.703)。在IBS症状4个领域的分项得分中,两组间腹泻症状得分的时间效应有显著差异(p = 0.017)。为期4周的多菌种益生菌混合物给药显著提高了IBS患者粪便中大多数益生菌菌株的浓度,并改善了腹泻症状得分。
J Gastroenterol Hepatol. 2014-1
Rev Esp Enferm Dig. 2013-1
Gastroenterol Clin Biol. 2008-2
Gut Microbiome (Camb). 2022-8-25
Food Sci Biotechnol. 2024-6-20
Curr Ther Res Clin Exp. 2023-10-18
Cochrane Database Syst Rev. 2023-2-17
Microorganisms. 2022-6-30
J Gastroenterol Hepatol. 2014-1
Clin Gastroenterol Hepatol. 2012-3-15
J Altern Complement Med. 2012-2
Eur J Gastroenterol Hepatol. 2012-1